我要投票 土博士在兽药行业中的票数:443
· 外 推 电 报 ·
2025-08-25 00:44:06 星期一

【土博士是哪个国家的品牌?】

土博士是什么牌子?「土博士」是 重庆永健生物技术有限责任公司 旗下著名品牌。该品牌发源于重庆市,由创始人李 * 旭在2001年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力土博士品牌出海!将品牌入驻外推网,定制土博士品牌推广信息,可以显著提高土博士产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

重庆永健生物技术有限责任公司(简称永健生物)位于国家农牧高新技术产业开发区——重庆荣昌高新区,始建于2001年5月,由原四川畜牧兽医学院院长、动物传染病学专家佘永健教授及其弟子们投资创建,2017年12月同华派生物工程集团实现了战略合作,掀开了集团化发展的新篇章。是专业从事兽用精制卵黄抗体及高新生化制剂研发、生产、销售和技术增值服务为一体的技术企业,是国内较早精制蛋黄抗体GMP生产企业。

永健生物现有员工193人,其中教授8人,博士4人,硕士13人,高级兽医师1人,执业兽医师18人,大专以上学历82人。公司拥有土博士动物药品生产厂、SPF实验动物房、现代化高免蛋鸡养殖基地、P3级标准生物实验室、动物疫病诊断中心、生物技术研究所,以及重庆尚上生物技术研究所有限公司和重庆乎文生物技术有限公司。

永健生物坚持自主研发与联合研发相结合,先后与中科院、军事医学科学院、西南大学、南京农大、东北农大、江苏农科院、福建农科院、国家兽用生物制品工程技术研究中心,以及国家动物用保健品工程技术研究中心等科研院校建立了战略合作关系,狠抓新产品开发与市场开拓,产品销售网络不仅遍布全国所有省市,还远销埃塞俄比亚、缅甸、沙特阿拉伯、苏丹等海外多个国家。

永健生物通过近二十载的努力,公司现有精制蛋黄抗体、干扰素、转移因子、中药提取、水针、粉针、口服液、粉(散)剂、预混剂等各种剂型的生物、化学、中草药制剂百余种,已基本形成为现代生态畜牧业畜禽疾病预防保健与治疗药品安全供应和养殖技术咨询服务的保障平台。

大华派、新永健,志存高远,永行永健。我们始终坚持以客户需求为中心,以市场和员工为基本点,以二十多年的抗体研究为基础,多元并举的发展方向,坚守“专业化、规范化、品牌化、信息化”的四化发展道路。永健人始终信奉“科学技术是第一生产力”的精辟论断,矢志以知识创新、技术创新、产品创新、服务创新和管理创新铸百年永健品牌,为全人类的绿色健康养殖事业贡献我们的力量。


英文翻译:Chongqing Yongjian Biotechnology Co., Ltd. (hereinafter referred to as Yongjian Biology) is located in Chongqing Rongchang high tech Industrial Development Zone, a national high tech Industrial Development Zone for agriculture and animal husbandry. It was founded in May 2001 by Professor she Yongjian, the former president of Sichuan Institute of animal husbandry and veterinary medicine and an expert in animal infectious diseases, and his disciples. In December 2017, it realized strategic cooperation with huapai bioengineering group and opened a collection A new chapter in the development of collectivization. It is a technical enterprise specializing in the research and development, production, sales and technical value-added services of refined yolk antibody and high-tech biochemical preparations for animal use, and an earlier GMP manufacturer of refined yolk antibody in China. Yongjian biology has 193 employees, including 8 professors, 4 doctors, 13 masters, 1 senior veterinarian, 18 practicing veterinarians, 82 with college degree or above. The company owns Dr. Tu animal medicine factory, SPF laboratory animal house, modern high immune layer breeding base, P3 standard biological laboratory, animal disease diagnosis center, Biotechnology Research Institute, Chongqing Shangshang Biotechnology Research Institute Co., Ltd. and Chongqing Huwen Biotechnology Co., Ltd. Yongjian biology adheres to the combination of independent R & D and joint R & D, and has successively established strategic cooperation relations with scientific research institutions such as Chinese Academy of Sciences, Academy of Military Medical Sciences, Southwest University, Nanjing Agricultural University, Northeast Agricultural University, Jiangsu Academy of Agricultural Sciences, Fujian Academy of Agricultural Sciences, national animal biological products engineering technology research center, and national animal health care products engineering technology research center, etc., and pays close attention to new products Development and market development, product sales network not only all provinces and cities across the country, but also exported to Ethiopia, Myanmar, Saudi Arabia, Sudan and other overseas countries. Through nearly 20 years' efforts, Yongjian biological has more than 100 kinds of biological, chemical and Chinese herbal medicine preparations, including refined egg yolk antibody, interferon, transfer factor, traditional Chinese medicine extraction, water injection, powder injection, oral liquid, powder (powder) agent, premix, etc., which have basically become the modern ecological animal husbandry animal disease prevention and health care and treatment drug safety supply and breeding technology consultation Service guarantee platform. Dahua school, new Yongjian, has a long-standing ambition and a long way to go. We always adhere to the development direction of taking customer demand as the center, market and employees as the basic points, antibody research for more than 20 years as the basis, multiple and simultaneous development, and adhere to the four development paths of "specialization, standardization, branding and informatization". Yongjian people always believe in the incisive conclusion that "science and technology is the first productivity", and are committed to building a century old Yongjian brand with knowledge innovation, technology innovation, product innovation, service innovation and management innovation, so as to contribute our strength to the green and healthy breeding of the whole mankind.

本文链接: https://www.waitui.com/brand/616acacb6.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

格林美:筹划发行H股股票并在香港联交所上市

36氪获悉,格林美发布公告,经充分研究论证,董事会同意公司发行H股股票并在香港联合交易所有限公司(简称“香港联交所”)主板挂牌上市。公司将充分考虑现有股东的利益和境内外资本市场的情况,在股东会决议有效期内(即经公司股东会审议通过之日起24个月或同意延长的其他期限)选择适当的时机和发行窗口完成本次发行上市。截至目前,公司正积极与相关中介机构就本次发行上市的相关工作进行商讨,除本次董事会、监事会审议通过的相关议案外,其他关于本次发行上市的具体细节尚未最终确定。

44分钟前

中信证券:预计未来中国前列腺癌RDC诊疗市场将超100亿元

36氪获悉,中信证券研报表示,创新核药RDC有望解决目前前列腺癌诊疗过程中检测负担大、疗效有限等未被满足临床需求,改变前列腺癌诊疗范式,实现诊疗一体化,提高患者依从性和生存期。目前中国尚无任何RDC上市,市场呈现蓝海状态,海外前列腺癌RDC诊疗产品在2021年上市,2024年市场已接近30亿美元,充分验证了其巨大的商业价值。中信证券认为中国有望复刻海外前列腺癌RDC诊疗市场发展路径,预计未来中国前列腺癌RDC诊疗市场将超100亿元,市场呈现高速增长状态。该行业关键点为核素、配体分子形态、生产配送能力,建议关注在上述条件具有优势的公司。

45分钟前

​锡业股份:上半年净利润10.62亿元,同比增长32.76%

36氪获悉,锡业股份披露2025年半年报,上半年实现营业收入210.93亿元,同比增长12.35%;归属于上市公司股东的净利润10.62亿元,同比增长32.76%;基本每股收益0.626元。

45分钟前

亚世光电:上半年净利润538.04万元,同比下降36.21%

36氪获悉,亚世光电披露2025年半年报,上半年实现营业收入4.32亿元,同比增长30.01%;归属于上市公司股东的净利润538.04万元,同比下降36.21%;基本每股收益0.0331元。

45分钟前

金螳螂:上半年净利润3.58亿元,同比增长3.95%

36氪获悉,金螳螂披露2025年半年报,上半年实现营业收入95.28亿元,同比增长2.49%;归属于上市公司股东的净利润3.58亿元,同比增长3.95%;基本每股收益0.1348元。

45分钟前

本页详细列出关于土博士的品牌信息,含品牌所属公司介绍,土博士所处行业的品牌地位及优势。
咨询